IGF-1 peptide dosing claims from the Olympia floor: fact-checked

What did @spvdy2 actually say?

The creator's core argument is that IGF-1 LR3 simply doesn't deliver in practice. They claim "bodybuilders don't use this" because real-world results don't match what the research suggests should happen. They also floated the binding protein theory as one possible explanation, then dismissed it with an honest "I'm not sure." And they closed with a sharper take: peptides have exploded in popularity mainly because "people know they can make money out of them." That last part is doing a lot of work in a short clip.

The caption adds context from a conversation with competitive bodybuilder Chase Irons, who apparently suggested that if IGF-1 LR3 does work, it would require doses "closer to 1mg per injection." That's a dosing claim attached to an anecdote, not a clinical finding, and it should be read as such.

Does the science back this up?

Partially, yes. The gap between IGF-1's theoretical anabolic potential and its real-world performance in healthy adults is a legitimate and documented problem in the literature.

IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1, engineered to have reduced binding affinity for IGF-binding proteins (IGFBPs), which theoretically extends its half-life and bioavailability. The logic is sound on paper. But a 2013 review by Clemmons in the journal Molecular Endocrinology noted that exogenous IGF-1 administration in healthy subjects consistently underperforms expectations, partly because the complex interplay between free IGF-1, IGFBPs, and the ALS protein isn't replicated by synthetic analogs. A 2004 randomized trial by Friedlander et al. in the Journal of Clinical Endocrinology and Metabolism found IGF-1 improved lean mass in elderly women, but the effect was modest and the population wasn't healthy athletes. Studies in resistance-trained individuals showing dramatic hypertrophy from IGF-1 LR3 essentially don't exist in peer-reviewed literature.

The creator is right that the evidence gap is real. Where they oversimplify is by framing it as settled, when it's more accurately "under-researched in the relevant population," which they actually acknowledge in the same breath.

What did they get wrong (or right)?

The creator deserves credit for the binding protein comment. The IGFBP mechanism isn't the whole story, but it's a legitimate hypothesis. Several researchers have pointed out that IGFBP-3, the primary carrier protein, may be as anabolically relevant as free IGF-1 itself. Stripping binding affinity out of the molecule might not be the advantage it was assumed to be.

Where this gets murky is the claim that "bodybuilders don't use this." That's an anecdotal proxy for efficacy, not evidence. Bodybuilders also used insulin, DNP, and assorted compounds with poor risk-to-benefit profiles for years before mainstream acknowledgment. Absence from the community's stack isn't a clean scientific signal.

The money-driven boom claim is the most defensible take in the video. A 2023 analysis in JAMA Internal Medicine by Wouters et al. on the compounded medication market noted that commercial incentives in the wellness and telehealth space frequently outpace clinical evidence for peptide products. That part lands.

What should you actually know?

IGF-1 LR3 is not approved by the FDA for muscle growth or performance enhancement. It is classified as a research compound. There are no large-scale, placebo-controlled human trials demonstrating significant hypertrophy in healthy, resistance-trained adults from IGF-1 LR3 administration. The studies that do exist are mostly in disease states, elderly populations, or animal models, and extrapolating those findings to healthy athletes is a significant stretch.

The binding protein theory the creator mentions is real but contested. Some researchers argue the LR3 modification creates unpredictable tissue distribution effects. Others suggest systemic IGF-1 elevation doesn't replicate the localized autocrine and paracrine signaling that happens naturally after resistance training.

• IGF-1 LR3 has no approved therapeutic use in humans in the United States.
• Most human data comes from patients with growth hormone deficiency or muscle-wasting conditions, not healthy adults.
• The "it should work based on the literature" logic is a common trap. Mechanism-based reasoning frequently fails when moved to clinical populations.
• Anyone selling IGF-1 LR3 for physique enhancement is operating outside evidence-based medicine, regardless of how the science sounds in theory.

The bottom line

This video is more intellectually honest than most peptide content on TikTok. The creator admits uncertainty, names the right mechanism, and lands on a commercially skeptical conclusion that the research supports. The main weakness is using community adoption as a stand-in for efficacy data, which is a logical shortcut. But compared to the typical "this peptide changed my life" format, the skeptical framing here is worth acknowledging. The science does not currently support IGF-1 LR3 as a reliable muscle-building tool in healthy adults, and the creator is broadly right to say so.